Literature DB >> 15581966

Neoadjuvant high-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages IIIa-IVa cervical cancer.

Satoru Motoyama1, Shinya Hamana, Yonson Ku, Jovelle B Laoag-Fernandez, Masashi Deguchi, Shigeki Yoshida, Masahiro Tominaga, Takeshi Iwasaki, Noriyuki Ohara, Takeshi Maruo.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the response rate and survival of patients with locally advanced uterine cervical cancer who were treated with intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration (PPPEC).
METHODS: Twenty-three untreated patients with stages IIIa-IVa cervical cancer were enrolled in the study. PPPEC was administered twice at 2 weeks interval using high-dose cisplatin alone (140-250 mg/m(2)) or high-dose cisplatin plus mitomycin C (7 mg/m(2)), pepleomycin (7 mg/m(2)) and 5-fluorouracil (700 mg/m(2)). Eighteen patients in whom the tumor downstaging was confirmed underwent radical surgery following PPPEC, whereas in the remaining five patients, radiotherapy was administered.
RESULTS: Two weeks after the second PPPEC, the median volumetric tumor reduction and tumor response were 76% and 87%, respectively. Histologic response was 96%, while the tumor downstaging reached 83%. The curative surgery rate achieved was 89%. Five-year progression-free survival was 47% and 5-year survival rate was 74%.
CONCLUSION: High-dose intraarterial infusion chemotherapy under PPPEC effectively achieved tumor downstaging and resulted in the favorable performance of the subsequent radical surgery and improved the 5-year survival rate of patients with locally advanced uterine cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15581966     DOI: 10.1016/j.ygyno.2004.08.027

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

Review 1.  Recent progress in histochemistry and cell biology.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2012-02-25       Impact factor: 4.304

2.  Distribution study of peplomycin in rat kidney revealed by immunocytochemistry using monoclonal antibodies.

Authors:  Kunio Fujiwara; Masashi Shin; David M Hougaard; Tetsuya Saita
Journal:  Histochem Cell Biol       Date:  2010-12-14       Impact factor: 4.304

3.  The negative-balance isolated pelvic perfusion method using ultrahigh-dose cisplatin for invasive bladder cancer with poor risk.

Authors:  Ryoji Kimata; Yukihiro Kondo; Kaoru Nemoto; Satoru Murata; Tatsuo Kumazaki
Journal:  Int J Clin Oncol       Date:  2010-04-21       Impact factor: 3.402

4.  Long-term follow-up of neoadjuvant intraarterial chemotherapy using an original four-lumen double-balloon (4L-DB) catheter for locally advanced uterine cervical cancer.

Authors:  Yoshito Terai; Masanori Kanemura; Hiroshi Sasaki; Satoshi Tsunetoh; Yoshimichi Tanaka; Yoshiki Yamashita; Kazuhiro Yamamoto; Isamu Narabayashi; Masahide Ohmichi
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

5.  Single-dose intra-arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB-IIB cervical cancer.

Authors:  Kiyoshi Yoshino; Ayako Hosoi; Keigo Osuga; Takayuki Enomoto; Yutaka Ueda; Kenjiro Sawada; Seiji Mabuchi; Eiji Kobayashi; Koji Matsuo; Tadashi Kimura
Journal:  Mol Clin Oncol       Date:  2016-04-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.